BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIOA BioAge Labs Inc.

Pre-Market Trading 11-22 07:46:56 EST

18.44

+0.04

+0.22%

High19.39	Low18.10	Vol216.65K
Open18.35	D1 Closing18.40	Amplitude7.03%
Mkt Cap661.05M	Tradable Cap193.62M	Total Shares35.85M
T/O3.98M	T/O Rate2.06%	Tradable Shares10.50M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BIOA","market":"US","secType":"STK","nameCN":"BioAge Labs Inc.","latestPrice":18.44,"timestamp":1732222800000,"preClose":18.4,"halted":0,"volume":216649,"delay":0,"floatShares":10500000,"shares":35848738,"eps":-33.128242,"marketStatus":"Pre-Market Trading","change":0.04,"latestTime":"11-22 07:46:56 EST","open":18.35,"high":19.3933,"low":18.1,"amount":3975344.789781,"amplitude":0.070288,"askPrice":21,"askSize":1000,"bidPrice":17.5,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-33.128242,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732285800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1727323200000,"exchange":"NASDAQ","adjPreClose":18.44,"postHourTrading":{"tag":"盘后","latestPrice":18.44,"preClose":18.44,"latestTime":"16:00 EST","volume":1092,"amount":20136.48,"timestamp":1732222808690},"volumeRatio":1.0487302385425252},"requestUrl":"/m/hq/s/BIOA","defaultTab":"news","newsList":[{"id":"2485254854","title":"BioAge Labs to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2485254854","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485254854?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:30","pubTimestamp":1732224600,"startTime":"0","endTime":"0","summary":"RICHMOND, Calif., Nov.  21, 2024  (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for met","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/21/2985645/0/en/BioAge-Labs-to-Present-at-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA"],"gpt_icon":0},{"id":"2482717964","title":"BioAge Labs Reports Strong Q3 2024 Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2482717964","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482717964?lang=en_us&edition=fundamental","pubTime":"2024-11-12 12:01","pubTimestamp":1731384109,"startTime":"0","endTime":"0","summary":"BioAge Labs, Inc. ( ($BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors. Bi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bioage-labs-reports-strong-q3-2024-achievements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bioage-labs-reports-strong-q3-2024-achievements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2481157694","title":"Bioage Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481157694","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481157694?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:30","pubTimestamp":1731015001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA4SSJ1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2481150324","title":"BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481150324","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481150324?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:30","pubTimestamp":1731015000,"startTime":"0","endTime":"0","summary":"Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents su","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/07/2977256/0/en/BioAge-Labs-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2481600145","title":"BrainTransporter™ dramatically improves antibody delivery to the brain","url":"https://stock-news.laohu8.com/highlight/detail?id=2481600145","media":"PR Newswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481600145?lang=en_us&edition=fundamental","pubTime":"2024-11-06 22:18","pubTimestamp":1730902680,"startTime":"0","endTime":"0","summary":"STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- BioArctic AB    has presented the design of its proprietary BrainTransporter  platform at the 16thannual Protein & Antibody Engineering Summit  conference in Barcelona, Spain. The BT platform uses active Transferrin Receptor -mediated transport, enabling up to 70-fold higher penetration of antibodies over the blood brain barrier, without negative effects on hematological safety parameters.During the 16th annual Protein & Antibody Engineering Summit  Europe conference, Dr. Per-Ola Freskgrd, VP Science & Technology at BioArctic, presented for the first time the design of the proprietary BT platform as well as validation in preclinical models.Brain uptake of biotherapeutics such as antibodies and enzymes is severely limited by the blood brain barrier  primarily due to their size. Active transport across the BBB, using one of the body's own delivery mechanisms, aims to enable better drug uptake into the brain. The BT technology utilizes the Transferr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VVNrxfnBjgBvfMmk.bDvuw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/e9c2cdd340683fe35a4079b1c027f1c1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VVNrxfnBjgBvfMmk.bDvuw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/e9c2cdd340683fe35a4079b1c027f1c1"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/braintransporter-dramatically-improves-antibody-delivery-141800023.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/braintransporter-dramatically-improves-antibody-delivery-141800023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BT","B","BIOA","BK4007","BK4161"],"gpt_icon":1},{"id":"2480868605","title":"BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2480868605","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480868605?lang=en_us&edition=fundamental","pubTime":"2024-11-04 22:00","pubTimestamp":1730728800,"startTime":"0","endTime":"0","summary":"Two presentations to highlight increased weight loss in obese mice treated with azelaprag in combination with multiple oral appetite suppressants, and significant protection against weight gain with a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/04/2974138/0/en/BioAge-Labs-to-Present-Preclinical-Data-for-APJ-Agonist-Azelaprag-at-ObesityWeek-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA"],"gpt_icon":0},{"id":"2477635691","title":"BioAge Labs to Present at Jefferies London Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2477635691","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477635691?lang=en_us&edition=fundamental","pubTime":"2024-10-24 21:00","pubTimestamp":1729774800,"startTime":"0","endTime":"0","summary":"RICHMOND, Calif., Oct.  24, 2024  (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/24/2968764/0/en/BioAge-Labs-to-Present-at-Jefferies-London-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","BIOA","BK4137"],"gpt_icon":0},{"id":"2477381717","title":"Bioage Labs Inc : Citigroup Initiates Coverage With Buy Rating; Target Price $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2477381717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477381717?lang=en_us&edition=fundamental","pubTime":"2024-10-22 18:51","pubTimestamp":1729594313,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nFWN3LY0K4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2477950862","title":"Wall Street analysts initiate coverage of BioAge Labs","url":"https://stock-news.laohu8.com/highlight/detail?id=2477950862","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477950862?lang=en_us&edition=fundamental","pubTime":"2024-10-21 22:53","pubTimestamp":1729522403,"startTime":"0","endTime":"0","summary":"Investing.com --BioAge Labs, a clinical-stage biotech company developing therapies for metabolic diseases, has attracted attention from Wall Street investment banks, with three analysts initiating coverage of the stock on Monday.The analysts are particularly focused on BioAge's lead asset, azelaprag, which has shown promise as an adjunct therapy to GLP-1-based weight loss treatments.Jefferies initiated coverage with a Buy rating and a price target of $42 a share, highlighting azelaprag's \"differentiated MOA\" as an exercise mimetic for obesity.Morgan Stanley launched coverage with an Overweight rating and a $40 price target, highlighting BioAge's collaboration with Eli Lilly  as a significant endorsement of the company's approach.\"We think arguably the most compelling reason to be bullish on BioAge is its partnership with Eli Lilly, which not only validates the company's approach  but provides potential optionality as Lilly has exclusive right of first negotiation with the Phase 2 resul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-initiate-coverage-145323288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","IE00B1BXHZ80.USD","BK4127","LU2237443465.HKD","IE0004086264.USD","IE0004091025.USD","LU0640476718.USD","LU1668664300.SGD","LU2237438978.USD","BK4581","LU0114720955.EUR","LU0417517546.SGD","IE00BKVL7J92.USD","LU0314104364.USD","LU0320765646.SGD","LU0109391861.USD","BK4588","LU0689472784.USD","LU0122379950.USD","LU0203202063.USD","LU1069344957.HKD","LU0385154629.USD","LU0096364046.USD","LU1791807156.HKD","IE0034235188.USD","LU1061106388.HKD","LU1074936037.SGD","IE00BJLML261.HKD","BK4007","LLY","LU0882574139.USD","IE0004445239.USD","LU0061475181.USD","LU1035775433.USD","LU1989772923.USD","LU0006306889.USD","LU0820561818.USD","BIOA","LU2237443622.USD","IE00B2B36J28.USD","IE00BK4W5L77.USD","LU0354030438.USD","LU2237443978.SGD","BK4516","LU0106261372.USD","BABA","LU0820561909.HKD","LU0079474960.USD","LU2237443895.HKD","GB00BDT5M118.USD","IE00B19Z3581.USD"],"gpt_icon":1},{"id":"2477856178","title":"BUZZ-Jefferies starts BioAge Labs with 'buy' on novel obesity drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2477856178","media":"Reuters","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477856178?lang=en_us&edition=fundamental","pubTime":"2024-10-21 19:34","pubTimestamp":1729510478,"startTime":"0","endTime":"0","summary":"** Jefferies initiates coverage of drug developer BioAge Labs    with \"buy\" rating and price target of $42    ** Brokerage says BIOA's lead candidate, azelaprag, has a novel mechanism to be used as an additional therapy with popular GLP-1 drugs for obesity and could help address certain unmet needs in an increasingly competitive market   ** BIOA plans to test its drug along with Eli Lilly's  Zepbound and Novo Nordisk's    Wegovy in mid-stage studies   ** Jefferies models peak revenues of nearly $2 bln for the drug; says it targets \"energy expenditure\" compared to energy intake that other drugs target   ** Based on early data, brokerage expects drug could help achieve more weight loss vs with Zepbound/Wegovy alone and with fewer side effects   ** Jefferies says azelaprag could also help preserve muscle mass while increasing fat loss and provide a convenient oral dosing alternative   ** As of last close, stock up ~30% since Nasdaq debut on Sept. 26 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BUZZ-Jefferies starts BioAge Labs with 'buy' on novel obesity drug","news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BJLML261.HKD","IE00B4R5TH58.HKD","IE00B1BXHZ80.USD","LU0820561909.HKD","LU0289739699.SGD","LU0320765059.SGD","LU1035775433.USD","LU0823416689.USD","IE00BJJMRZ35.SGD","BK4533","LU0471298694.HKD","IE00BK4W5L77.USD","LU0471298777.SGD","LU0203201768.USD","LU0256863902.USD","LU1093756168.USD","LU0198837287.USD","LU1061106388.HKD","LU0943347566.SGD","LU0094547139.USD","LU1064131342.USD","IE00B2B36J28.USD","LU0114720955.EUR","LU0354030438.USD","IE00BK4W5M84.HKD","LU0097036916.USD","LU0203202063.USD","LU0689472784.USD","LU0109391861.USD","GB00BDT5M118.USD","LU0079474960.USD","LU0417517546.SGD","BK4581","LU0106261372.USD","BK4534","LU0238689110.USD","LU0882574055.USD","IE0009355771.USD","LU0354030511.USD","LU0006306889.USD","IE0004445239.USD","LU0466842654.USD","BK4585","IE0002141913.USD","BIOA","LU0672654240.SGD","LU0640476718.USD","LU0708995401.HKD"],"gpt_icon":1},{"id":"2477688830","title":"Morgan Stanley Initiates BioAge Labs at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2477688830","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477688830?lang=en_us&edition=fundamental","pubTime":"2024-10-21 18:29","pubTimestamp":1729506561,"startTime":"0","endTime":"0","summary":"Morgan Stanley Initiates BioAge Labs at Overweight","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIOA"],"gpt_icon":0},{"id":"2477830500","title":"Jefferies Initiates BioAge Labs at Buy With $42 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2477830500","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477830500?lang=en_us&edition=fundamental","pubTime":"2024-10-21 18:29","pubTimestamp":1729506551,"startTime":"0","endTime":"0","summary":"Jefferies Initiates BioAge Labs at Buy With $42 Price Target","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIOA"],"gpt_icon":0},{"id":"2477978834","title":"BioAge Labs intiated with a Not Rated at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2477978834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477978834?lang=en_us&edition=fundamental","pubTime":"2024-10-21 17:30","pubTimestamp":1729503037,"startTime":"0","endTime":"0","summary":"Goldman Sachs initiated coverage of BioAge Labs (BIOA) with a Not Rated. The firm models for peak azelaprag sales of $8.5B in 2036 via peak penetra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-intiated-with-a-not-rated-at-goldman-sachs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-intiated-with-a-not-rated-at-goldman-sachs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IE00B19Z3581.USD","LU2237443465.HKD","IE00BSNM7G36.USD","LU2237443382.USD","LU2237443895.HKD","BK4504","BK4585","BK4550","IE0002270589.USD","LU2237443978.SGD","LU1791807156.HKD","IE0004091025.USD","BK4552","BK4007","LU1668664300.SGD","LU2237438978.USD","BIOA","IE0034235188.USD","BK4533","BK4127","LU2237443549.SGD","IE0004086264.USD","LU0106831901.USD","LU2237443622.USD","IE00BFXG1179.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2477839938","title":"BioAge Labs, Inc.: Promising Developments and Strategic Partnerships Lead to Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2477839938","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477839938?lang=en_us&edition=fundamental","pubTime":"2024-10-21 17:15","pubTimestamp":1729502143,"startTime":"0","endTime":"0","summary":"BioAge Labs, Inc. (BIOA) has received a new Buy rating, initiated by Morgan Stanley analyst, Jeffrey Hung. Jeffrey Hung’s rating is based on severa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bioage-labs-inc-promising-developments-and-strategic-partnerships-lead-to-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bioage-labs-inc-promising-developments-and-strategic-partnerships-lead-to-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA"],"gpt_icon":0},{"id":"2477483964","title":"BioAge Labs initiated with a Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2477483964","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477483964?lang=en_us&edition=fundamental","pubTime":"2024-10-21 17:10","pubTimestamp":1729501825,"startTime":"0","endTime":"0","summary":"Jefferies initiated coverage of BioAge Labs (BIOA) with a Buy rating and $42 price target BioAge is a clinical stage biotech focusing on metabolic ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-initiated-with-a-buy-at-jefferies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-initiated-with-a-buy-at-jefferies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2476784111","title":"Prediction: These 2 Stocks Could Soar in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2476784111","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476784111?lang=en_us&edition=fundamental","pubTime":"2024-10-17 21:45","pubTimestamp":1729172700,"startTime":"0","endTime":"0","summary":"The key word here is \"could.\"","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793607%2Fresearch-scientists-drugs-pharma-biotech.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793607%2Fresearch-scientists-drugs-pharma-biotech.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/10/17/prediction-these-2-stocks-could-soar-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["RXRX","IPO","BK4139","BK4548","BIOA","BK4539","BK4007"],"gpt_icon":0},{"id":"2475856303","title":"Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2475856303","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475856303?lang=en_us&edition=fundamental","pubTime":"2024-10-13 02:31","pubTimestamp":1728757860,"startTime":"0","endTime":"0","summary":"BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793569%2Fgettyimages-1166581794.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793569%2Fgettyimages-1166581794.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/10/12/interested-in-weight-loss-stocks-besides-novo-nord/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1093756325.SGD","LU0820561818.USD","LU0114720955.EUR","IE00BJJMRZ35.SGD","LU0466842654.USD","LU0109391861.USD","LU1023059063.AUD","LU0094547139.USD","LU0354030511.USD","LU0198837287.USD","LU1061106388.HKD","IE0009355771.USD","IE00BJT1NW94.SGD","IE00BJLML261.HKD","LU1093756168.USD","BK4585","GB00BDT5M118.USD","LU1057294990.SGD","LU1035775433.USD","LU0689472784.USD","BK4532","LU0256863811.USD","LU0882574055.USD","IE0002141913.USD","IPO","BK4007","IE00BFTCPJ56.SGD","LU0006306889.USD","LU0471298694.HKD","LU0354030438.USD","BIOA","LU0943347566.SGD","IE00B1BXHZ80.USD","LU0708995401.HKD","BK4581","LU0079474960.USD","IE00BKVL7J92.USD","LU0289739699.SGD","LLY","LU0385154629.USD","LU0061475181.USD","LU0820561909.HKD","LU0122379950.USD","LU0882574139.USD","LU1069344957.HKD","LU0097036916.USD","LU0096364046.USD","NVO","IE0004445239.USD","LU0058720904.USD"],"gpt_icon":1},{"id":"2473452908","title":"RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2473452908","media":"GuruFocus.com","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473452908?lang=en_us&edition=fundamental","pubTime":"2024-10-08 09:10","pubTimestamp":1728349827,"startTime":"0","endTime":"0","summary":"On September 27, 2024, RA Capital Management, L.P., a prominent investment firm, made a significant move in the biopharmaceutical sector by acquiring 2,210,589 shares of Bioage Labs Inc . This transaction, valued at $21 per share, marks a new holding for the firm, reflecting a strategic investment in the healthcare industry. The acquisition not only diversifies RA Capital's portfolio but also underscores its commitment to investing in innovative companies tackling major healthcare challenges.Based in Boston, RA Capital Management, L.P. is renowned for its focus on healthcare and financial services sectors. With a robust portfolio that includes top holdings like Ascendis Pharma AS  and Rhythm Pharmaceuticals Inc , the firm manages an equity portfolio worth approximately $7.56 billion. RA Capital's investment philosophy emphasizes substantial engagement in sectors that promise significant technological or therapeutic advancements.The acquisition of a 0.61% position in Bioage Labs by RA C","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/JTt5bo0JSKtQ3XtJrY3fJQ--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/9802aef1fe4cb0ac29db2bff39d71eb6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/JTt5bo0JSKtQ3XtJrY3fJQ--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/9802aef1fe4cb0ac29db2bff39d71eb6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ra-capital-management-l-p-011027241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4588","NQmain","PSQ","LU0889565916.HKD","RYTM","QID",".IXIC","ASND","MNQmain","LU0320765992.SGD","LU0109394709.USD","RA","TQQQ","QLD","BK4139","BIOA","SQQQ"],"gpt_icon":1},{"id":"2473161087","title":"Regeneron co-founder warns of harms from weight-loss drugs: FT","url":"https://stock-news.laohu8.com/highlight/detail?id=2473161087","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473161087?lang=en_us&edition=fundamental","pubTime":"2024-10-06 22:29","pubTimestamp":1728224971,"startTime":"0","endTime":"0","summary":"The co-founder of biotech firm Regeneron Pharmaceuticals (NASDAQ:REGN) said in a newspaper interview that popular weight-loss drugs could be harmful to people who lose too much muscle mass that’s seen","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1498835905/image_1498835905.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1498835905/image_1498835905.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4156605-regeneron-co-founder-warns-of-harms-from-weight-loss-drugs-ft","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU0256863811.USD","NONOF","LU0094547139.USD","IE00B1BXHZ80.USD","LU0109391861.USD","LU2362541273.HKD","LU0354030511.USD","LU0289739699.SGD","LU0053666078.USD","IE00BJT1NW94.SGD","LU0471298694.HKD","LU1057294990.SGD","LU2362540622.SGD","IE00BK4W5L77.USD","NVO","LLY","IE00BK4W5M84.HKD","LU0122379950.USD","LU2089984988.USD","LU1093756325.SGD","LU0061475181.USD","LU0320765992.SGD","GB00BDT5M118.USD","LU2362541513.USD","LU0006306889.USD","LU0943347566.SGD","LU0354030438.USD","LU0114720955.EUR","LU1093756168.USD","IE00BZ1G4Q59.USD","LU0820561909.HKD","IE0004445239.USD","LU1035775433.USD","BIOA","IE00BJJMRZ35.SGD","LU1023059063.AUD","BK4581","LU2468319806.SGD","IE0002141913.USD","LU0096364046.USD","IE00BJLML261.HKD","BK4533","REGN","LU0058720904.USD","LU0882574055.USD","LU1061106388.HKD","LU0708995401.HKD","LU0079474960.USD","BK4534","BK4532"],"gpt_icon":0},{"id":"2473227976","title":"3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October","url":"https://stock-news.laohu8.com/highlight/detail?id=2473227976","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473227976?lang=en_us&edition=fundamental","pubTime":"2024-10-05 19:15","pubTimestamp":1728126900,"startTime":"0","endTime":"0","summary":"There's a chance that its lead candidate could become one of the top drugs ever.","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F792597%2Fscientist-gestures-to-diagram-on-whiteboard.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F792597%2Fscientist-gestures-to-diagram-on-whiteboard.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/10/05/3-reasons-to-buy-bioage-labs-stock-hand-over-fist/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["IPO","LU0757428866.USD","LU1815336091.USD","BK4124","VC","BIOA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://bioagelabs.com","stockEarnings":[{"period":"1week","weight":-0.0548},{"period":"1month","weight":-0.2236},{"period":"3month","weight":0.0244},{"period":"ytd","weight":0.0244}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":" ","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.008123},{"month":2,"riseRate":0.4,"avgChangeRate":-0.16094},{"month":3,"riseRate":0.2,"avgChangeRate":-0.091972},{"month":4,"riseRate":0.4,"avgChangeRate":-0.044244},{"month":5,"riseRate":0,"avgChangeRate":-0.19738},{"month":6,"riseRate":0.25,"avgChangeRate":0.003055},{"month":7,"riseRate":0.4,"avgChangeRate":-0.005696},{"month":8,"riseRate":0.4,"avgChangeRate":-0.229124},{"month":9,"riseRate":0.6,"avgChangeRate":0.004924},{"month":10,"riseRate":0.8,"avgChangeRate":0.181962},{"month":11,"riseRate":0.6,"avgChangeRate":0.056827},{"month":12,"riseRate":0.2,"avgChangeRate":-0.087267}],"exchange":"NASDAQ","name":"BioAge Labs Inc.","nameEN":"BioAge Labs Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioAge Labs Inc.(BIOA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioAge Labs Inc.,BIOA,BioAge Labs Inc.股票,BioAge Labs Inc.股票老虎,BioAge Labs Inc.股票老虎国际,BioAge Labs Inc.行情,BioAge Labs Inc.股票行情,BioAge Labs Inc.股价,BioAge Labs Inc.股市,BioAge Labs Inc.股票价格,BioAge Labs Inc.股票交易,BioAge Labs Inc.股票购买,BioAge Labs Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioAge Labs Inc.(BIOA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}